You are here: Home: Audio Program Guide: PCU 3 | 2008 Audio: PCU 3 | 2008
 
 

Go to Prostate Cancer Journal Club


 
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     

 
Prostate Cancer Journal Club  
Track 1 Stephenson AJ et al. Prostate cancer-specific mortality after radical prostatectomy in the prostate-specific antigen era. Genitourinary Cancers Symposium 2008.
Track 2 Time course of recurrence in prostate cancer
Track 3 Horwitz EM et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26(15):2497-504.
Track 4 D’Amico AV et al. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008;26(18):2979-83.
Track 5 D’Amico AV et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008;299(3):289-95.
Track 6 Roach M III et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008;26(4):585-91.

Track 7 Alibhai SM et al. Impact of androgen deprivation therapy (ADT) on bone, cardiovascular, and endocrine outcomes: A propensity-matched analysis of 20,000 patients. Proc ASCO 2008.
Track 8 Camara C et al. High prevalence of metabolic syndrome in patients under long-term hormonal therapy for prostate cancer. Preliminary report. Proc AUA 2008.
Track 9 Donovan MJ et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008;26(24):3923-9.
Track 10 Enhanced prognostic and predictive information with systems pathology
Track 11 Potential role of Ki-67 in the systems pathology platform
Track 12 Donovan MJ et al. Androgen receptor levels in both needle biopsy and prostatectomy specimens are associated with overall survival in castration resistant disease. Genitourinary Cancers Symposium 2008.

Track 13 Figg WD et al. Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy. Proc ASCO 2008.
Track 14 Clinical trials evaluating bevacizumab and sunitinib in prostate cancer
Track 15 Flaig TW et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008;26(9):1532-6.
Track 16 Dawson N et al. Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: Results of a phase II trial. Genitourinary Cancers Symposium 2008.
Track 17 Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71.

Track 18 Lu-Yao GL et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300(2):173-81.